Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gillies Mcindoe Research Institute currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution of this portfolio is concentrated under 1 distinct examiner and 1 distinct art unit. This level of focus indicates that the institute's current patenting activity is confined to a specific technical and administrative path.
The busiest examiner for this portfolio is SOROUSH, LAYLA, who is responsible for 1 busiest examiner pending office action. Since the portfolio only involves 1 distinct examiner, SOROUSH, LAYLA is managing the total volume of pending actions for the institute. This creates a singular point of contact for the institute's current legal challenges within the patent office.
The 1 distinct art unit involved suggests that the research being patented falls under a single technical classification. The 1 pending office action represents the entire current workload for the institute's patent portfolio. This streamlined data profile highlights a prosecution environment where all active matters are subject to the review of 1 distinct examiner in 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17795779 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMANGIOMA | SOROUSH, LAYLA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17795779 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMANGIOMA | SOROUSH, LAYLA | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17795779 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMANGIOMA | SOROUSH, LAYLA | 1622 | §102§103 | Non-Final OA | — | Pending | Jul 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGillies Mcindoe Research Institute has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Layla Soroush has the most, with 1 of Gillies Mcindoe Research Institute's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
